MaxCyte Reports Mixed Q1 2026 Results Revenue Dips While Expenses Decline Tech Sits Out the US IPO Rush as Biotech and Healthcare Stocks Flock to Go Public Chemed CHE Q1 2026 Beat Revenue NA EPS Exceeds by Significant Tenax Therapeutics TENX Stalls at 1194 Consolidation Phase 20260514 Irish Inflation Rises to 27Month High Adding Pressure on Consumer Prices Is RGC Resources RGCO Undervalued at 2324 20260514 Walker WD Delivers Q1 2026 Beat EPS 046 vs 028 Expected